(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Arrow Exploration brings new Colombian oil well on stream ahead of schedule and under budget - 2Iran begins cloud seeding to induce rain amid historic drought
- 3US bishops officially ban gender-affirming care at Catholic hospitals
- 4Saucony's $125 'Comfy, Stylish' Sneakers Are Now $55
- 5Glamour Shots once ruled the mall. I went to one of the last ones standing.
- 5 Fundamental Ways to employ a Criminal Legal counselor
- These 45 exoplanets may be the best places to search for alien life
- If you want a true taste of Italian paradise, head to Favignana
- This Week In Space podcast: Episode 188 — A New NASA Leader Rises?
- How many ships have been attacked in the Gulf since start of Iran war?
- Popular Japanese Hotel Chain Now Lets You Show Up With Just Your Passport
- Argentina joins NASA’s moon return with microsatellite testing GPS beyond Earth
- Colorado residents face earliest water restrictions ever — a harbinger of worse to come
- Instructions to Pick the Right Toothpaste for Your Dental Requirements
